UA125600C2 - Лікування холестатичного свербежу - Google Patents

Лікування холестатичного свербежу Download PDF

Info

Publication number
UA125600C2
UA125600C2 UAA202001861A UAA202001861A UA125600C2 UA 125600 C2 UA125600 C2 UA 125600C2 UA A202001861 A UAA202001861 A UA A202001861A UA A202001861 A UAA202001861 A UA A202001861A UA 125600 C2 UA125600 C2 UA 125600C2
Authority
UA
Ukraine
Prior art keywords
pruritus
seladelpar
day
cholestatic
treatment
Prior art date
Application number
UAA202001861A
Other languages
English (en)
Ukrainian (uk)
Inventor
Пол Буд
Чарлз А. МакВертер
Александра С. Стейнберг
Original Assignee
Сімабей Терапьютікс, Інк.
Симабей Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сімабей Терапьютікс, Інк., Симабей Терапьютикс, Инк. filed Critical Сімабей Терапьютікс, Інк.
Publication of UA125600C2 publication Critical patent/UA125600C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ladders (AREA)
UAA202001861A 2017-09-26 2018-09-24 Лікування холестатичного свербежу UA125600C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762563395P 2017-09-26 2017-09-26
PCT/US2018/052490 WO2019067373A1 (en) 2017-09-26 2018-09-24 TREATMENT OF CHOLESTATIC PRURIT

Publications (1)

Publication Number Publication Date
UA125600C2 true UA125600C2 (uk) 2022-04-27

Family

ID=64564950

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202001861A UA125600C2 (uk) 2017-09-26 2018-09-24 Лікування холестатичного свербежу

Country Status (26)

Country Link
US (2) US20190105291A1 (enExample)
EP (3) EP3973959B8 (enExample)
JP (1) JP7023371B2 (enExample)
KR (1) KR102376794B1 (enExample)
CN (1) CN111132675B (enExample)
AU (2) AU2018342323B2 (enExample)
BR (1) BR112020005074A2 (enExample)
CA (1) CA3076614C (enExample)
CY (1) CY1124894T1 (enExample)
DK (1) DK3973959T3 (enExample)
ES (2) ES3012120T3 (enExample)
FI (1) FI3973959T3 (enExample)
HR (2) HRP20250022T1 (enExample)
HU (2) HUE057377T2 (enExample)
IL (2) IL273569B (enExample)
LT (2) LT3973959T (enExample)
MX (1) MX392537B (enExample)
PL (2) PL3687523T3 (enExample)
PT (2) PT3973959T (enExample)
RS (1) RS62790B1 (enExample)
SG (1) SG11202002253SA (enExample)
SI (2) SI3687523T1 (enExample)
SM (1) SMT202200171T1 (enExample)
UA (1) UA125600C2 (enExample)
WO (1) WO2019067373A1 (enExample)
ZA (1) ZA202001646B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR20220140762A (ko) * 2020-02-10 2022-10-18 장피트 엘라피브라노에 의한 원발 담즙성 담관염의 치료
CN116490191A (zh) * 2020-10-20 2023-07-25 葛兰素史克知识产权第二有限公司 治疗胆汁淤积性瘙痒的方法
HUE066653T2 (hu) 2021-02-01 2024-08-28 Cymabay Therapeutics Inc Cholangiopathiák kezelése seladelparral
EP4654957A1 (en) 2023-01-29 2025-12-03 CymaBay Therapeutics, Inc. Treatment of uremic pruritus
KR20250139304A (ko) 2023-01-29 2025-09-23 사이머베이 쎄라퓨틱스, 인코퍼레이티드 만성 소양증 피부병의 치료

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1667964T3 (pl) 2003-09-19 2010-01-29 Janssen Pharmaceutica Nv Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
PL3119384T3 (pl) * 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
US20200276178A1 (en) * 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists

Also Published As

Publication number Publication date
CY1124894T1 (el) 2023-01-05
ES3012120T3 (en) 2025-04-08
KR102376794B1 (ko) 2022-03-18
RU2020114644A3 (enExample) 2022-02-14
CN111132675B (zh) 2023-04-25
EP3973959A1 (en) 2022-03-30
EP3973959B1 (en) 2024-12-11
US20210283078A1 (en) 2021-09-16
JP2020535225A (ja) 2020-12-03
LT3687523T (lt) 2022-03-25
IL288340A (en) 2022-01-01
ZA202001646B (en) 2021-08-25
US20190105291A1 (en) 2019-04-11
JP7023371B2 (ja) 2022-02-21
PT3687523T (pt) 2021-12-06
SI3973959T1 (sl) 2025-03-31
WO2019067373A1 (en) 2019-04-04
IL288340B1 (en) 2023-01-01
EP3973959B8 (en) 2025-01-15
KR20200058458A (ko) 2020-05-27
HUE057377T2 (hu) 2022-05-28
RU2020114644A (ru) 2021-10-27
IL273569B (en) 2021-12-01
SI3687523T1 (sl) 2022-05-31
PL3973959T3 (pl) 2025-03-24
CA3076614A1 (en) 2019-04-04
BR112020005074A2 (pt) 2020-09-15
AU2021254641B2 (en) 2022-02-24
LT3973959T (lt) 2025-01-10
AU2021254641A1 (en) 2021-11-18
CA3076614C (en) 2023-02-07
IL288340B2 (en) 2023-05-01
IL273569A (en) 2020-05-31
EP4523744A2 (en) 2025-03-19
HRP20250022T1 (hr) 2025-03-14
EP3687523A1 (en) 2020-08-05
MX2020007273A (es) 2022-05-23
MX392537B (es) 2025-03-04
PL3687523T3 (pl) 2022-02-21
AU2018342323A1 (en) 2020-04-16
SMT202200171T1 (it) 2022-05-12
PT3973959T (pt) 2025-01-24
EP3687523B1 (en) 2021-11-03
AU2018342323B2 (en) 2021-09-23
NZ762976A (en) 2021-11-26
HRP20212010T1 (hr) 2022-04-01
EP4523744A3 (en) 2025-06-04
RS62790B1 (sr) 2022-02-28
FI3973959T3 (fi) 2025-02-03
CN111132675A (zh) 2020-05-08
SG11202002253SA (en) 2020-04-29
HUE070033T2 (hu) 2025-05-28
ES2902349T3 (es) 2022-03-28
DK3973959T3 (da) 2025-01-20

Similar Documents

Publication Publication Date Title
UA125600C2 (uk) Лікування холестатичного свербежу
EP3119384B1 (en) Treatment of intrahepatic cholestatic diseases
JPS6241688B2 (enExample)
US11224580B2 (en) Treatment of intrahepatic cholestatic diseases
JP7079735B2 (ja) 肝内胆汁うっ滞性疾患の処置
HK40062783B (en) Treatment of cholestatic pruritus with seladelpar
HK40121699A (en) Treatment of cholestatic pruritus
RU2781281C2 (ru) Лечение холестатического зуда
HK40062783A (en) Treatment of cholestatic pruritus with seladelpar
HK40033446B (en) Treatment of cholestatic pruritus with seladelpar
HK40033446A (en) Treatment of cholestatic pruritus with seladelpar
NZ762976B2 (en) Treatment of cholestatic pruritus
HK1229212A1 (en) Treatment of intrahepatic cholestatic diseases
HK1229212B (en) Treatment of intrahepatic cholestatic diseases
WO2013036844A2 (en) Methods for treatment of and prophylaxis against hemorrhoids